Eligibility criteria and recruitment
rhabdomyolysis, epilepsy, cirrhosis, brain infection, diabetes
RHABDOMYOLYSIS, EPILEPSY, CIRRHOSIS, HEPATITIS C, ADVERSE DRUG REACTIONS, DIABETES
Patients, men and women aged between 20 to 45 years old, using stable ART (no adverse drug reactions, no pregnancy or current illnesses, understand lifelong adherence, and evidence of successful treatment) for at least a year with positive CMV IgG and viral load of HIV RNA <50 copies/mL are recruited to the study. Viral load, anti-CMV antibody, and lipid panel tests are done before defining the eligibility criteria. Participants are also required to not use any statin therapy 6 weeks before enrollment. Patients with the following conditions are excluded from the study:patients undergoing hepatitis C DAA therapydecompensated cirrhosis or acute liver failurehistory of coronary artery diseasehistory of diabetes mellitushistory of brain infection, epilepsy, or strokehistory of rhabdomyolysis or myopathypregnant or breastfeeding during studysevere depressionpatients using statin therapy in the 6 weeks prior to the studyhistory of statin hypersensitivitypatients with a Framingham Risk Score above 10% within LDL ≥130